Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Depreciation & Amortization (CF) (2016 - 2025)

Lineage Cell Therapeutics (LCTX) has 16 years of Depreciation & Amortization (CF) data on record, last reported at $186000.0 in Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) rose 23.18% year-over-year to $186000.0; the TTM value through Dec 2025 reached $699000.0, up 19.08%, while the annual FY2025 figure was $699000.0, 19.08% up from the prior year.
  • Depreciation & Amortization (CF) reached $186000.0 in Q4 2025 per LCTX's latest filing, up from $178000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $186000.0 in Q4 2025 and bottomed at $138000.0 in Q1 2023.
  • Average Depreciation & Amortization (CF) over 5 years is $153176.5, with a median of $146000.0 recorded in 2022.
  • Peak YoY movement for Depreciation & Amortization (CF): decreased 17.92% in 2021, then increased 26.24% in 2025.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $174000.0 in 2021, then dropped by 18.97% to $141000.0 in 2022, then rose by 1.42% to $143000.0 in 2023, then increased by 5.59% to $151000.0 in 2024, then rose by 23.18% to $186000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Depreciation & Amortization (CF) were $186000.0 in Q4 2025, $178000.0 in Q3 2025, and $171000.0 in Q2 2025.